如何提高慢性髓性白血病患者获得无治疗缓解资格的可能性?
本文综述了提高慢性髓性白血病(CML)患者无治疗缓解(TFR)资格的策略。早期研究如法国STIM试验显示40%至50%的患者停药后维持深度分子学反应(DMR),多数复发发生在最初6个月内。综述讨论了早期干预转换、联合治疗、DMR缺失时主动转换、剂量优化及诱导-维持方案等可能改善分子学反应并提高TFR资格的策略。
要点
- TFR已成为CML管理中的重要临床终点,部分患者可在维持DMR后停用酪氨酸激酶抑制剂(TKI)。
- 早期研究显示40%至50%的患者停药后维持DMR,多数复发发生在最初6个月内。
- 早期干预转换、联合治疗、DMR缺失时主动转换、剂量优化及诱导-维持方案可能提高TFR资格。
核心结论
- 早期干预转换至最佳反应、联合治疗、DMR缺失时主动转换、剂量优化及诱导-维持方案可能改善分子学反应,从而提高TFR资格。
研究设计与样本
- 本文为综述,报告并讨论了可能提高首次TFR尝试资格的所有潜在治疗策略,重点关注未来可能的方法。
主要发现
- 早期研究如法国STIM试验显示,40%至50%的患者停药后维持DMR,多数复发发生在最初6个月内。
- 已确定的成功TFR关键预后因素包括治疗持续时间、DMR持续时间、风险评分和转录本类型。
关键数值与推荐
- TFR定义为停用TKI后维持DMR。
- 早期研究显示停药后维持DMR的比例为40%至50%,多数复发发生在最初6个月内。
- 成功TFR的关键预后因素包括治疗持续时间、DMR持续时间、风险评分和转录本类型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The achievement of treatment-free remission (TFR) has become a significant clinical end-point in the management of patients with chronic myeloid leukaemia (CML), providing an opportunity to discontinue therapy with tyrosine kinase inhibitors (TKIs) while maintaining deep molecular response (DMR). Early studies, such as the French STIM trial, have demonstrated that a portion of patients can maintain DMR after treatment cessation, with rates ranging from 40% to 50%, and most relapses occurring within the first 6 months. Key prognostic factors for successful TFR, including treatment duration, duration of DMR, risk scores, and transcript type, have been identified. Optimal patient selection for TFR remains a challenge, but recent research provides insights into potential strategies to increase TFR eligibility. Evidence suggests that early intervention switching to achieve optimal response, treatment combinations, proactive switch in the case of absence of DMR, dose-optimization and induction-maintenance approach can improve molecular responses and, consequently, enhance TFR eligibility. In this review, we report and discuss all the potential therapeutic strategies that may enhance eligibility for a first attempt at TFR, with a particular emphasis on potential future approaches.
引用
- Costa A, Breccia M. How to improve treatment-free remission eligibility in chronic myeloid leukaemia? Br J Haematol. 2023. PMID: 38148564. doi:10.1111/bjh.19269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。